Novo Nordisk A/S (NVO) SEC Filings: History & Chart

Novo Nordisk A/S (NVO)NVONovo Nordisk A/S

About Novo Nordisk A/S

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Bagsvaerd, CR

77,406 employees

www.novonordisk.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Maziar Mike Doustdar

View full financials

Form	Filing Date	Accepted	Document
6-K	Jul 31, 2026	Jul 31, 2026	View filing
6-K	Jul 27, 2026	Jul 27, 2026	View filing
6-K	Jul 21, 2026	Jul 21, 2026	View filing
6-K	Jul 13, 2026	Jul 13, 2026	View filing
6-K	Jul 6, 2026	Jul 6, 2026	View filing
6-K	Jun 29, 2026	Jun 29, 2026	View filing
6-K	Jun 24, 2026	Jun 24, 2026	View filing
SC 13G/A	Jun 22, 2026	Jun 22, 2026	View filing
11-K	Jun 22, 2026	Jun 18, 2026	View filing
11-K	Jun 22, 2026	Jun 18, 2026	View filing
6-K	Jun 15, 2026	Jun 15, 2026	View filing
6-K	Jun 8, 2026	Jun 8, 2026	View filing
6-K	Jun 1, 2026	Jun 1, 2026	View filing
6-K	May 27, 2026	May 27, 2026	View filing
6-K	May 22, 2026	May 22, 2026	View filing
SD	May 22, 2026	May 22, 2026	View filing
6-K	May 22, 2026	May 22, 2026	View filing
6-K	May 18, 2026	May 18, 2026	View filing
6-K	May 13, 2026	May 13, 2026	View filing
6-K	May 6, 2026	May 6, 2026	View filing
6-K	May 5, 2026	May 5, 2026	View filing
6-K	Apr 27, 2026	Apr 27, 2026	View filing
6-K	Apr 20, 2026	Apr 20, 2026	View filing
6-K	Apr 20, 2026	Apr 20, 2026	View filing
6-K	Apr 13, 2026	Apr 13, 2026	View filing
SC 13G/A	Apr 10, 2026	Apr 10, 2026	View filing
6-K	Apr 7, 2026	Apr 7, 2026	View filing
6-K	Mar 30, 2026	Mar 30, 2026	View filing
6-K	Mar 27, 2026	Mar 27, 2026	View filing
6-K	Mar 27, 2026	Mar 27, 2026	View filing

SEC Filings

Recent Filings